SEARCH:   Advanced

Blood, 1 August 2006, Vol. 108, No. 3, pp. 836-846. Prepublished online as a Blood First Edition Paper on April 4, 2006; DOI 10.1182/blood-2005-11-4503. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-11-4503v1 108/3/836    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Martino, R. Articles by de Witte, T. Search for Related Content PubMed PubMed Citation Articles by Martino, R. Articles by de Witte, T. Related Collections Neoplasia Transplantation Free Research Articles Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes Rodrigo Martino, Simona Iacobelli, Ronald Brand, Thekla Jansen, Anja van Biezen, Jürgen Finke, Andrea Bacigalupo, Dietrich Beelen, Jossy Reiffers, Agnes Devergie, Emilie Alessandrino, Ghulam J. Mufti, Renée Barge, Jorge Sierra, Tapani Ruutu, Marc Boogaerts, Michele Falda, Jean-Pierre Jouet, Dieter Niederwieser, Theo de Witte, for the Myelodysplastic Syndrome subcommittee of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation Group From the Division of Clinical Hematology, Hospital de la Sant Creu i Sant Pau, Autonomous University of Barcelona, Spain; Department of Medical Statistics, University of Leiden, the Netherlands; Chronic Leukemia Working Party Registry, Leiden, the Netherlands; Department of Medicine, Hematology and Oncology, University of Freiburg, Germany; Department of Hematology, Ospedale San Martino, Genova, Italy; Department of Bone Marrow Transplantation, University Hospital, Essen, Germany; Centre Hopitalier Universitaire (CHU) Bordeaux, Hopital Haut-Leveque, Pessac, France; Department of Hematology, Hopital St Louis, Paris, France; Policlinico San Matteo Instituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Pavia, Italy; Department of Hematology, King's College London School of Medicine, London, United Kingdom; Department of Hematology, Leiden University Medical Center (LUMC), Leiden, the Netherlands; Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland; Department of Hematology, University Hospital of Leuven, Belgium; Centro Trapianti Midollo, Azienda Ospedaliera S. Giovanni, Torino, Italy; Service de Maladies du Sang, Hopital Claude Huriez, Lille, France; Department of Internal Medicine, University Hospital Leipzig, Germany; and the Department of Hematology, Radboud University Medical Center Nijmegen, the Netherlands. In this multicenter retrospective study, the outcomes of 836 patients with myelodysplastic syndrome (MDS) who underwent transplantation with a human leukocyte antigen (HLA)–identical sibling donor were analyzed according to 2 types of conditioning: reduced-intensity conditioning (RIC) in 215 patients, and standard myeloablative (or high-dose) conditioning (SMC) in 621 patients. In multivariate analysis, the 3-year relapse rate was significantly increased after RIC (hazard ratio [HR], 1.64; 95% confidence interval [95% CI], 1.2-2.2; P = .001), but the 3-year nonrelapse mortality (NRM) rate was decreased in the RIC group (HR, 0.61; 95% CI, 0.41-0.91; P = .015). The 3-year probabilities of progression-free and overall survivals were similar in both groups (39% after SMC vs 33% in RIC; multivariate P = .9; and 45% vs 41%, respectively; P = .8). In conclusion, the lower 3-year NRM after RIC is encouraging, since these patients were older (age > 50 years in 73% RIC vs 28% in SMC, P < .001) and had more adverse pretransplantation variables. However, based on the higher risk of relapse, patients with no contraindications for SMC should not receive RIC outside of prospective randomized trials, which are needed to establish the position of RIC-based transplantation in the treatment of patients with MDS. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: RIC for MDS: the glass is half full David L. Porter Blood 2006 108: 780-781. [Full Text] [PDF] This article has been cited by other articles: E. Jabbour, H. Kantarjian, D. Jones, M. Breeden, G. Garcia-Manero, S. O'Brien, F. Ravandi, G. Borthakur, and J. Cortes Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy Blood, July 1, 2008; 112(1): 53 - 55. [Abstract] [Full Text] [PDF] M. L. Sorror, B. M. Sandmaier, B. E. Storer, M. B. Maris, F. Baron, D. G. Maloney, B. L. Scott, H. J. Deeg, F. R. Appelbaum, and R. Storb Comorbidity and Disease Status Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation J. Clin. Oncol., September 20, 2007; 25(27): 4246 - 4254. [Abstract] [Full Text] [PDF] D. Blaise, N. Vey, C. Faucher, and M. Mohty Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia Haematologica, April 1, 2007; 92(4): 533 - 541. [Abstract] [Full Text] [PDF] C. A. Schiffer Clinical Issues in the Management of Patients with Myelodysplasia Hematology, January 1, 2006; 2006(1): 205 - 210. [Abstract] [Full Text] [PDF] B. L. Scott and B. M. Sandmaier Outcomes with Myeloid Malignancies Hematology, January 1, 2006; 2006(1): 381 - 389. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020